Document is current
Any future updates will be listed below
-
Authors
Holm Nielsen, Signe https://orcid.org/0000-0002-4612-1014
Sardar, Samra https://orcid.org/0000-0002-5016-3671
Siebuhr, Anne Sofie https://orcid.org/0000-0003-0802-8422
Schlemmer, Annette
Schmidt, Erik Berg https://orcid.org/0000-0002-0623-5666
Bay-Jensen, Anne-Christine https://orcid.org/0000-0001-7952-9297
Karsdal, Morten A. https://orcid.org/0000-0001-5026-8740
Christensen, Jeppe Hagstrup https://orcid.org/0000-0003-1208-833X
Kristensen, Salome https://orcid.org/0000-0001-5812-5234
-
Funding
Funding for this research was provided by:
Den Danske Forskningsfond
Innovationsfonden
Dansk Rheumatologisk selskab
Danish Psoriasis Foundation
- License Information
-
More Information
Article History
Received: 3 December 2020
Accepted: 7 April 2021
First Online: 22 April 2021
Declarations
:
: SHN, ASS, ACBJ and MAK are full-time employees at Nordic Bioscience A/S. Nordic Bioscience is a privately-owned, small–medium size enterprise (SME) partly focused on the development of biomarkers. None of the authors received fees, bonuses or other benefits for the work described in the manuscript. MAK and ACBJ hold stocks in Nordic Bioscience A/S.
: All participants gave their written informed consent and the regional ethics committee of North Denmark approved the study (Reference number N20120076). The study was conducted in accordance with the Declaration of Helsinki and registered at ClinicalTrials.gov (NCT01818804).
